PASTIC Dspace Repository

Optimization of empagliflozin immediate release tablets (10 mg) using central composite rotatable design with response surface methodology

Show simple item record

dc.contributor.author M. Hanif, Anas
dc.contributor.author Bushra, Rabia
dc.contributor.author Iffat, Wajiha
dc.contributor.author Ghayas, Sana
dc.contributor.author Perveen, Shaheen
dc.contributor.author Riaz, Humayun
dc.contributor.author Alam, Shazia
dc.contributor.author Ali, Syed Imran
dc.contributor.author Ismail, Nahlah Elkudssiah
dc.contributor.author Zeb-un-Nisa
dc.date.accessioned 2022-10-19T06:03:27Z
dc.date.available 2022-10-19T06:03:27Z
dc.date.issued 2021-07-20
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/13278
dc.description.abstract Empagliflozin is a selective inhibitor of sodium glucose co-transporter II, given as mono therapy or an add-on treatment to reduce the glycated hemoglobin levels in type 2 diabetes. This work deals with designing, formulating and optimizing empagliflozin (10mg) immediate release (IR) tablets by direct compression technique using different excipients. Through central composite rotatable design (CCRD), total nine formulations (EF1-EF9) were generated by changing the composition of binder avicel PH 102® (X1) and superdisintegrant acdisol® (X2). Formulation runs with in suitable weight range and powder properties were subjected to compression. The influence of interaction of excipients on friability (Y1), hardness (Y2) and disintegration (Y3) were analyzed by fitting the polynomial quadratic model with response surface methodology (RSM). Trials EF2, EF7, EF8 and EF9 exhibited acceptable tablet attributes upon physico-chemical testing. Different dissolution models were applied to observe the in vitro drug release pattern in phosphate buffer of pH 6.8. The cumulative drug release of IR tablet batches followed the Weibull kinetics with regression coefficient (r 2 ) values of 0.983-0.992. Empagliflozin trials were exposed to accelerated storage conditions (40±2°C/ 75±5% RH) for stability testing. Shelf life period of exposed formulations were computed in range of 22 to 25 months. Keeping in view of the results, it is concluded that the employed technique of preparation and optimization are observed to be excellent for developing immediate release empagliflozin (10mg) tablets. en_US
dc.language.iso en en_US
dc.publisher Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi en_US
dc.subject Empagliflozin en_US
dc.subject optimization en_US
dc.subject direct compression en_US
dc.subject response surface methodology en_US
dc.subject central composite rotatable design en_US
dc.title Optimization of empagliflozin immediate release tablets (10 mg) using central composite rotatable design with response surface methodology en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account